Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors

US9108956B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Sejal Patel · Cambridge, US
• Justin Yik Ching Mao · North Reading, US
• Qian Liu · Suzhou, CN
• Tyler Harrison · Somerville, US
• Rohit Duvadie · San Diego, US
• Xin Chen · Lexington, US
• Frederic Zecri · Cambridge, US

Key dates

• Filing date: Apr 26, 2013
• Grant date: Aug 18, 2015
• Expiry date: Apr 26, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.